11 recruiting, 6 completed, 2 active not recruiting, 2 not yet recruiting. 16 Phase 2, 8 Phase 1, 1 Not applicable.
Follow Acute Leukemia of Ambiguous Lineage: new trials by email Literature Review of Acute Leukemia of Ambiguous Lineage trials Research Report on Acute Leukemia of Ambiguous Lineage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms Biospecimen Collection, Bone Marrow Collection, Electronic Health Record Review - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-10-13 | 2026-10-19 |
| A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias JNJ-75276617, Fludarabine, Cytarabine - Acute Leukemias, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2025-12-26 | 2025-06-22 | |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-21 |
| Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Leukemia, Acute Leukemia of Ambiguous Lineage | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2024-12-31 | 2026-10-19 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-07-22 |
| Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial EBX-102, Placebo - Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage | Phase 2 | Recruiting | Imperial College London | 50 | 2024-05-01 | 2025-04-17 |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Revumenib, Venetoclax, Azacitidine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 24 | 2024-04-19 | 2026-10-22 |
| Venetoclax Combined With Azactidine in the Treatment of ALAL Venetoclax, azactidine - Acute Leukemia of Ambiguous Lineage | Phase 2 | Recruiting | Sheng-Li Xue, MD | 23 | 2023-07-01 | 2025-12-16 |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage vincristine, daunorubicin, cyclophosphamide - Acute Leukemia of Ambiguous Lineage | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2020-07-08 | 2025-08-06 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation revumenib, cobicistat - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Syndax Pharmaceuticals | 447 | 2019-11-05 | 2026-10-09 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kura Oncology, Inc. | 263 | 2019-09-12 | 2026-05-13 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Azacitidine, Biospecimen Collection, Computed Tomography - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2017-04-01 | 2025-02-27 |
| Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Completed | University of Washington | 50 | 2016-12-30 | 2022-03-08 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Clofarabine, Cytarabine, Dexamethasone - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2014-10-27 | 2024-03-22 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (23) · Leukemia, Myeloid, Acute (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Burkitt Lymphoma (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Myelodysplastic Syndromes (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4) · Leukemia (3) · Blast Crisis (2) · Leukemia, Mast-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myelomonocytic, Chronic (2) · Myeloproliferative Disorders (2) · Recurrence (2) · Anemia, Refractory, with Excess of Blasts (1)
Hematologic Diseases (23) · Hemic and Lymphatic Diseases (23) · Immune System Diseases (23) · Immunoproliferative Disorders (23) · Leukemia, Lymphoid (23) · Lymphatic Diseases (23) · Lymphoproliferative Disorders (23) · Neoplasms (23) · Neoplasms by Histologic Type (23) · Leukemia (20) · Leukemia, Myeloid (15) · Bone Marrow Diseases (8) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8)
Cytarabine (10) · Methotrexate (9) · Cyclophosphamide (8) · Specimen Handling (8) · Dexamethasone (7) · Vincristine (7) · Whole-Body Irradiation (6) · dexamethasone 21-phosphate (5) · dexamethasone acetate (5) · fludarabine phosphate (5) · merphos (5) · Biopsy (4) · Calcium Dobesilate (4) · Daunorubicin (4) · Leucovorin (4)
Fred Hutchinson Cancer Center (7) · National Cancer Institute (NCI) (2) · Andrew E. Place, MD (1) · City of Hope Medical Center (1) · Imperial College London (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Janssen Research & Development, LLC (1) · Kura Oncology, Inc. (1) · M.D. Anderson Cancer Center (1) · Nohla Therapeutics, Inc. (1) · SWOG Cancer Research Network (1) · Seattle Children's Hospital (1) · Sheng-Li Xue, MD (1) · St. Jude Children's Research Hospital (1) · Syndax Pharmaceuticals (1)
United States (18) · Canada (4) · Puerto Rico (3) · Australia (2) · China (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · Belgium (1) · Israel (1) · Lithuania (1) · Netherlands (1) · United Kingdom (1)
Marie Bleakley (3) · Ann Dahlberg (2) · Andrew E Place, MD, PhD (1) · Angela R Smith, M.D. (1) · Anna Halpern (1) · Brian Ball, MD (1) · Elias Jabbour (1) · Erin H Breese (1) · Filippo Milano, MD, PhD (1) · Hiroto Inaba, MD, PhD (1) · Ibrahim Aldoss (1) · Jacob Appelbaum, MD, PhD (1) · Jiri Pavlu (1) · Phuong Vo, MD (1)
PMID 33741715, PMID 34267079, PMID 35007144, PMID 33049057, PMID 36922593, PMID 38867582, PMID 39121437, PMID 39362248, PMID 39773995, PMID 40332046, PMID 40997296, PMID 41621809
P01CA018029 (3), P30CA015704 (3), R01HL121568 (2), U10CA180886 (2), K23CA154532 (1), P30CA033572 (1), U10CA180888 (1)